Astellas’ Phase III gastric cancer therapy trial meets primary endpoint

Astellas Pharma has reported that the Phase III GLOW clinical trial of zolbetuximab plus CAPOX as a first-line therapy to treat Claudin 18.2 (CLDN18.2)-positive, HER2-negative, locally advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers met the primary endpoint.